Weakness in Abiomed’s fiscal Q4 had been well telegraphed but was still worse than expected, Jefferies analyst Raj Denhoy tells investors in a research note. However, he believes issues with Impella use are being addressed and points out that April saw an uptick from March. The company’s fiscal 2020 guidance of 17%-23% “seems doable,” adds Denhoy. He lowered his price target for the shares to $330 from $460 and keeps a Buy rating on the name. The analyst believes now is the time to own Abiomed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.